Trials / Unknown
UnknownNCT03472352
Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Hangzhou Converd Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | An anticancer medication (A01) and immune cells (IC01) | The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2018-03-21
- Last updated
- 2018-03-21
Source: ClinicalTrials.gov record NCT03472352. Inclusion in this directory is not an endorsement.